secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001140361-25-006745
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics FY24 revenue $426.5M (+65% YoY); raises FY25/26 guidance
-----------------------------------------------------------------------

- FY 2024 total revenue $426.5M (+65% YoY); GAAP net income $197.7M incl. $84.3M tax benefit; Adjusted EBITDA $164.6M (+309% YoY).
- Q4 2024 revenue $117.5M (+59% YoY); GAAP net income $111.9M vs net loss of $17.6M; Adjusted EBITDA $48.3M vs $18.6M.
- FY 2025 revenue guidance raised to >$490M; FY 2026 >$605M; expects >$1B total revenue before 2030.
- FDA approval of yield enhancement process expected mid-2025, potentially increasing IG yields ~20%; long-term plasma supply from ~250 centers.
- Form 10-K filing delayed to on or before March 18, 2025 due to need for additional time to test internal controls with KPMG.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125006745/0001140361-25-006745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125006745/ef20044777_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-006745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer